ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Clinical trials for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on tough leukemia
Disease control Recruiting nowThis early-phase study is testing the safety and best dose of a two-drug combination (Vyxeos and gilteritinib) for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation and has returned or not responded to prior treatment. The goal is to see if this…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test Dual-Attack strategy for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and finding the best dose of a new two-drug combination (SNDX-5613 and gilteritinib) for adults with a specific form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The drugs work together to block two…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test new leukemia Pill's heart safety on healthy people
Knowledge-focused Recruiting nowThis is an early safety study to see if a potential new drug for a type of leukemia (AML with FLT3 mutation) affects the heart's electrical rhythm. It will involve 45 to 75 healthy Chinese volunteers who will take a single dose of the drug, a placebo, or a comparison drug. Resear…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd • Aim: Knowledge-focused
Last updated Mar 12, 2026 13:50 UTC